Skip to main content

Table 3 Association of CYP2D6 testing and therapeutic decision-making by CYP2D6 phenotypes

From: Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

CYP2D6phenotype Still on tamoxifen Changed to AIs No therapy Total P a Taking co-medications Changed co-medication P a
Ultra-rapid (UM)/extensive metabolizer (EM)b 156 (84%) 10 (5%) 20 (11%) 186   38 (21%) 9 (5%)  
Intermediate metabolizer (IM) 28 (88%) 1 (3%) 3 (9%) 32 0.51 8 (25%) 2 (3%) 0.62
Poor metabolizer (PM) 4 (31%) 6 (46%) 3 (23%) 13 < 0.001 0 0 -
Total 188 17 26 231   46 11  
  1. aP-value based on Fisher's exact test of association versus UM/EM. bUltra-rapid metabolizer (UM) data combined with extensive metabolizer (EM) data. AI, aromatase inhibitor.